查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873362

化膿性汗腺炎治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Hidradenitis Suppurativa Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球化膿性汗腺炎治療市場規模估計為 6.98 億美元，預計到 2031 年將達到 9.27 億美元，在預測期（2025-2031 年）內以 4.2% 的複合年成長率成長。

化膿性汗腺炎（HS）是一種疼痛的慢性皮膚病，可導致膿瘍和疤痕形成。雖然確切原因尚不清楚，但HS通常發生在毛囊周圍，即汗腺所在之處，主要分佈於鼠蹊部、臀部、乳房和腋窩。目前根治性，但治療方法和生活方式的改變可以幫助緩解症狀並減少發作頻率。

化膿性汗腺炎(HS) 治療市場的主要驅動力是人們對這種慢性且常被忽視的皮膚病的認知和診斷水平的提高。隨著越來越多的皮膚科醫生和基層醫療提供者對 HS 的早期症狀有了更深入的了解，早期診斷和介入也變得越來越普遍。此外，諸如 TNF-α 抑制劑（例如Adalimumab）等先進生物製藥的日益普及，正在將 HS 的治療從症狀治療轉變為標靶緩解疾病治療。病患權益倡導工作的活性化、新興市場醫療保健服務的改善以及對皮膚病學研發的持續投入，都進一步推動了市場成長。

儘管取得了這些進展，化膿性汗腺炎（HS）治療市場仍面臨許多挑戰。其中最主要的障礙之一是生物製藥高成本且醫療覆蓋範圍有限，尤其是在中低收入國家。此外，目前針對中重度病例的治療方法效果有限，且尚無治療方法，根治性患者不滿並最終中斷治療。診斷延遲、社會歧視以及新興治療方法缺乏臨床試驗數據也限制了市場擴張，並為製藥公司和醫療服務提供者帶來了持續的挑戰。

腋窩膿瘍的治療方法包括藥物治療、手術治療等，其中藥物治療在2019年約佔76%。腋窩膿瘍的治療在醫院、診所和其他醫療機構廣泛進行。到2024年，醫院將佔據腋窩膿瘍治療的最大佔有率，達到53.53%。歐洲是最大的消費市場，到2024年將佔47.76%的市場。亞太地區將成為第二大消費市場，佔23.97%的市佔率。市場競爭日益激烈，艾伯維、默克、輝瑞、Astra Zeneca和GlaxoSmithKline Plc等公司在業界處於領先地位。

本報告旨在按地區/國家、類型和應用對全球腋窩膿瘍治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以銷售收入為指標，對腋窩膿瘍治療市場規模、估值和預測進行了呈現，以2024年為基準年，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定腋窩膿腫治療的業務和成長策略，評估市場競爭，分析公司在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • AbbVie
  • Merck
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Perrigo
  • Sun Pharma
  • Almirall
  • Bausch Health
  • Johnson & Johnson
  • UCB Pharma
  • Amgen
  • NCPC

按類型分類的細分市場

  • 製藥
  • 外科手術
  • 其他

應用領域

  • 醫院
  • 診所
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Hidradenitis Suppurativa Treatment was estimated to be worth US$ 698 million in 2024 and is forecast to a readjusted size of US$ 927 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin. The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits. There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.

The Hidradenitis Suppurativa (HS) treatment market is primarily driven by the increasing awareness and diagnosis rates of this chronic and under-recognized skin condition. As more dermatologists and primary care providers are educated on the early signs of HS, earlier diagnosis and intervention are becoming more common. Additionally, the growing availability of advanced biologic therapies, such as TNF-a inhibitors (e.g., Adalimumab), is transforming HS management from symptomatic relief to targeted disease-modifying treatment. The rise in patient advocacy, increased healthcare access in emerging markets, and continuous investment in dermatological R&D are further fueling market growth.

Despite these advances, the HS treatment market faces several challenges. One of the most significant barriers is the high cost and limited reimbursement of biologic therapies, especially in low- and middle-income countries. Moreover, the limited efficacy of many current treatments for moderate to severe cases and the lack of a definitive cure contribute to patient frustration and discontinuation of therapy. Delayed diagnosis, social stigma, and limited clinical trial data for emerging therapies also restrict broader market expansion and pose ongoing hurdles for pharmaceutical companies and healthcare providers.

The classification of Hidradenitis Suppurativa Treatment includes Medications, Surgery and others, and the proportion of Medications in 2019 is about 76%. Hidradenitis Suppurativa Treatment is widely used in Hospital, Clinical and other field. The most proportion of Hidradenitis Suppurativa Treatment is Hospital, and the proportion in 2024 is 53.53%. Europe is the largest consumption place with a consumption market share of 47.76% in 2024. Following Europe, Asia Pacific is the second largest consumption place with the consumption market share of 23.97%. Market competition is intense. AbbVie, Merck, Pfizer, AstraZeneca, GlaxoSmithKline, etc. are the leaders of the industry.

This report aims to provide a comprehensive presentation of the global market for Hidradenitis Suppurativa Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hidradenitis Suppurativa Treatment by region & country, by Type, and by Application.

The Hidradenitis Suppurativa Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hidradenitis Suppurativa Treatment.

Market Segmentation

By Company

  • AbbVie
  • Merck
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Perrigo
  • Sun Pharma
  • Almirall
  • Bausch Health
  • Johnson & Johnson
  • UCB Pharma
  • Amgen
  • NCPC

Segment by Type

  • Medications
  • Surgery
  • Others

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Hidradenitis Suppurativa Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Hidradenitis Suppurativa Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Hidradenitis Suppurativa Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Hidradenitis Suppurativa Treatment Product Introduction
  • 1.2 Global Hidradenitis Suppurativa Treatment Market Size Forecast (2020-2031)
  • 1.3 Hidradenitis Suppurativa Treatment Market Trends & Drivers
    • 1.3.1 Hidradenitis Suppurativa Treatment Industry Trends
    • 1.3.2 Hidradenitis Suppurativa Treatment Market Drivers & Opportunity
    • 1.3.3 Hidradenitis Suppurativa Treatment Market Challenges
    • 1.3.4 Hidradenitis Suppurativa Treatment Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Hidradenitis Suppurativa Treatment Players Revenue Ranking (2024)
  • 2.2 Global Hidradenitis Suppurativa Treatment Revenue by Company (2020-2025)
  • 2.3 Key Companies Hidradenitis Suppurativa Treatment Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Hidradenitis Suppurativa Treatment Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Hidradenitis Suppurativa Treatment
  • 2.6 Hidradenitis Suppurativa Treatment Market Competitive Analysis
    • 2.6.1 Hidradenitis Suppurativa Treatment Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Hidradenitis Suppurativa Treatment Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hidradenitis Suppurativa Treatment as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Medications
    • 3.1.2 Surgery
    • 3.1.3 Others
  • 3.2 Global Hidradenitis Suppurativa Treatment Sales Value by Type
    • 3.2.1 Global Hidradenitis Suppurativa Treatment Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Hidradenitis Suppurativa Treatment Sales Value, by Type (2020-2031)
    • 3.2.3 Global Hidradenitis Suppurativa Treatment Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Others
  • 4.2 Global Hidradenitis Suppurativa Treatment Sales Value by Application
    • 4.2.1 Global Hidradenitis Suppurativa Treatment Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Hidradenitis Suppurativa Treatment Sales Value, by Application (2020-2031)
    • 4.2.3 Global Hidradenitis Suppurativa Treatment Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Hidradenitis Suppurativa Treatment Sales Value by Region
    • 5.1.1 Global Hidradenitis Suppurativa Treatment Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Hidradenitis Suppurativa Treatment Sales Value by Region (2020-2025)
    • 5.1.3 Global Hidradenitis Suppurativa Treatment Sales Value by Region (2026-2031)
    • 5.1.4 Global Hidradenitis Suppurativa Treatment Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 5.2.2 North America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 5.3.2 Europe Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Hidradenitis Suppurativa Treatment Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 5.5.2 South America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.3.2 United States Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.4.2 Europe Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.5.2 China Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.6.2 Japan Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.7.2 South Korea Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
    • 6.9.2 India Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 AbbVie
    • 7.1.1 AbbVie Profile
    • 7.1.2 AbbVie Main Business
    • 7.1.3 AbbVie Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.1.4 AbbVie Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.1.5 AbbVie Recent Developments
  • 7.2 Merck
    • 7.2.1 Merck Profile
    • 7.2.2 Merck Main Business
    • 7.2.3 Merck Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.2.4 Merck Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Merck Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.3.4 Pfizer Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 AstraZeneca
    • 7.4.1 AstraZeneca Profile
    • 7.4.2 AstraZeneca Main Business
    • 7.4.3 AstraZeneca Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.4.4 AstraZeneca Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.4.5 AstraZeneca Recent Developments
  • 7.5 GlaxoSmithKline
    • 7.5.1 GlaxoSmithKline Profile
    • 7.5.2 GlaxoSmithKline Main Business
    • 7.5.3 GlaxoSmithKline Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.5.4 GlaxoSmithKline Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.5.5 GlaxoSmithKline Recent Developments
  • 7.6 Perrigo
    • 7.6.1 Perrigo Profile
    • 7.6.2 Perrigo Main Business
    • 7.6.3 Perrigo Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.6.4 Perrigo Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Perrigo Recent Developments
  • 7.7 Sun Pharma
    • 7.7.1 Sun Pharma Profile
    • 7.7.2 Sun Pharma Main Business
    • 7.7.3 Sun Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.7.4 Sun Pharma Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Sun Pharma Recent Developments
  • 7.8 Almirall
    • 7.8.1 Almirall Profile
    • 7.8.2 Almirall Main Business
    • 7.8.3 Almirall Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.8.4 Almirall Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Almirall Recent Developments
  • 7.9 Bausch Health
    • 7.9.1 Bausch Health Profile
    • 7.9.2 Bausch Health Main Business
    • 7.9.3 Bausch Health Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.9.4 Bausch Health Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Bausch Health Recent Developments
  • 7.10 Johnson & Johnson
    • 7.10.1 Johnson & Johnson Profile
    • 7.10.2 Johnson & Johnson Main Business
    • 7.10.3 Johnson & Johnson Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.10.4 Johnson & Johnson Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Johnson & Johnson Recent Developments
  • 7.11 UCB Pharma
    • 7.11.1 UCB Pharma Profile
    • 7.11.2 UCB Pharma Main Business
    • 7.11.3 UCB Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.11.4 UCB Pharma Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.11.5 UCB Pharma Recent Developments
  • 7.12 Amgen
    • 7.12.1 Amgen Profile
    • 7.12.2 Amgen Main Business
    • 7.12.3 Amgen Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.12.4 Amgen Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Amgen Recent Developments
  • 7.13 NCPC
    • 7.13.1 NCPC Profile
    • 7.13.2 NCPC Main Business
    • 7.13.3 NCPC Hidradenitis Suppurativa Treatment Products, Services and Solutions
    • 7.13.4 NCPC Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
    • 7.13.5 NCPC Recent Developments

8 Industry Chain Analysis

  • 8.1 Hidradenitis Suppurativa Treatment Industrial Chain
  • 8.2 Hidradenitis Suppurativa Treatment Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Hidradenitis Suppurativa Treatment Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Hidradenitis Suppurativa Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Hidradenitis Suppurativa Treatment Market Trends
  • Table 2. Hidradenitis Suppurativa Treatment Market Drivers & Opportunity
  • Table 3. Hidradenitis Suppurativa Treatment Market Challenges
  • Table 4. Hidradenitis Suppurativa Treatment Market Restraints
  • Table 5. Global Hidradenitis Suppurativa Treatment Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Hidradenitis Suppurativa Treatment Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Hidradenitis Suppurativa Treatment Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Hidradenitis Suppurativa Treatment
  • Table 10. Global Hidradenitis Suppurativa Treatment Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hidradenitis Suppurativa Treatment as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Hidradenitis Suppurativa Treatment Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Hidradenitis Suppurativa Treatment Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Hidradenitis Suppurativa Treatment Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Hidradenitis Suppurativa Treatment Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Hidradenitis Suppurativa Treatment Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Hidradenitis Suppurativa Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Hidradenitis Suppurativa Treatment Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Hidradenitis Suppurativa Treatment Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Hidradenitis Suppurativa Treatment Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Hidradenitis Suppurativa Treatment Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Hidradenitis Suppurativa Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Hidradenitis Suppurativa Treatment Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Hidradenitis Suppurativa Treatment Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Hidradenitis Suppurativa Treatment Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Hidradenitis Suppurativa Treatment Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value, (2026-2031) & (US$ Million)
  • Table 31. AbbVie Basic Information List
  • Table 32. AbbVie Description and Business Overview
  • Table 33. AbbVie Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of AbbVie (2020-2025)
  • Table 35. AbbVie Recent Developments
  • Table 36. Merck Basic Information List
  • Table 37. Merck Description and Business Overview
  • Table 38. Merck Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Merck (2020-2025)
  • Table 40. Merck Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. AstraZeneca Basic Information List
  • Table 47. AstraZeneca Description and Business Overview
  • Table 48. AstraZeneca Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of AstraZeneca (2020-2025)
  • Table 50. AstraZeneca Recent Developments
  • Table 51. GlaxoSmithKline Basic Information List
  • Table 52. GlaxoSmithKline Description and Business Overview
  • Table 53. GlaxoSmithKline Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of GlaxoSmithKline (2020-2025)
  • Table 55. GlaxoSmithKline Recent Developments
  • Table 56. Perrigo Basic Information List
  • Table 57. Perrigo Description and Business Overview
  • Table 58. Perrigo Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Perrigo (2020-2025)
  • Table 60. Perrigo Recent Developments
  • Table 61. Sun Pharma Basic Information List
  • Table 62. Sun Pharma Description and Business Overview
  • Table 63. Sun Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Sun Pharma (2020-2025)
  • Table 65. Sun Pharma Recent Developments
  • Table 66. Almirall Basic Information List
  • Table 67. Almirall Description and Business Overview
  • Table 68. Almirall Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Almirall (2020-2025)
  • Table 70. Almirall Recent Developments
  • Table 71. Bausch Health Basic Information List
  • Table 72. Bausch Health Description and Business Overview
  • Table 73. Bausch Health Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Bausch Health (2020-2025)
  • Table 75. Bausch Health Recent Developments
  • Table 76. Johnson & Johnson Basic Information List
  • Table 77. Johnson & Johnson Description and Business Overview
  • Table 78. Johnson & Johnson Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Johnson & Johnson (2020-2025)
  • Table 80. Johnson & Johnson Recent Developments
  • Table 81. UCB Pharma Basic Information List
  • Table 82. UCB Pharma Description and Business Overview
  • Table 83. UCB Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of UCB Pharma (2020-2025)
  • Table 85. UCB Pharma Recent Developments
  • Table 86. Amgen Basic Information List
  • Table 87. Amgen Description and Business Overview
  • Table 88. Amgen Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of Amgen (2020-2025)
  • Table 90. Amgen Recent Developments
  • Table 91. NCPC Basic Information List
  • Table 92. NCPC Description and Business Overview
  • Table 93. NCPC Hidradenitis Suppurativa Treatment Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Hidradenitis Suppurativa Treatment Business of NCPC (2020-2025)
  • Table 95. NCPC Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Hidradenitis Suppurativa Treatment Downstream Customers
  • Table 99. Hidradenitis Suppurativa Treatment Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Hidradenitis Suppurativa Treatment Product Picture
  • Figure 2. Global Hidradenitis Suppurativa Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Hidradenitis Suppurativa Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Hidradenitis Suppurativa Treatment Report Years Considered
  • Figure 5. Global Hidradenitis Suppurativa Treatment Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Hidradenitis Suppurativa Treatment Revenue in 2024
  • Figure 7. Hidradenitis Suppurativa Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Medications Picture
  • Figure 9. Surgery Picture
  • Figure 10. Others Picture
  • Figure 11. Global Hidradenitis Suppurativa Treatment Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Hidradenitis Suppurativa Treatment Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Hospitals
  • Figure 14. Product Picture of Clinics
  • Figure 15. Product Picture of Others
  • Figure 16. Global Hidradenitis Suppurativa Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Hidradenitis Suppurativa Treatment Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Hidradenitis Suppurativa Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Hidradenitis Suppurativa Treatment Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value (%), (2020-2031)
  • Figure 29. United States Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Hidradenitis Suppurativa Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Hidradenitis Suppurativa Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Hidradenitis Suppurativa Treatment Industrial Chain
  • Figure 51. Hidradenitis Suppurativa Treatment Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed